RESUMO
Malignant liver tumors have a high incidence and mortality rate. Therefore, it is of great significance to promptly learn about tumor advancement status through relevant examinations for patients' follow-up, diagnosis, and therapy as well as the improvement of the five-year survival rate. The primary lesions and intrahepatic metastases of malignant liver tumors have been better demonstrated in the clinical study with the use of various isotope-labeled fibroblast activating protein inhibitors because of their low uptake in liver tissues and high tumor/background ratio, which provides a new method for early diagnosis, precise staging, and radionuclide therapy. In light of this context, a review of the research progress of fibroblast-activating protein inhibitors for the diagnosis of liver malignant tumors is presented.
Assuntos
Humanos , Tomografia por Emissão de Pósitrons combinada à Tomografia Computadorizada , Carcinoma Hepatocelular , Neoplasias HepáticasRESUMO
Objective To investigate the diagnostic value of dual-tracer PET imaging in Alzheimer's disease (AD).Methods For this study,we enrolled 11 patients who were diagnosed clinically with AD and 7 age-matched healthy controls who underwent 11 C-PIB and 18 F-FDG PET brain imaging in the same period.Visual evaluation was used to observe the distribution of tracers.ROI technology and brain metabolism analysis software were used to quantify the uptake levels of PIB and FDG.Results Compared with that in HC group,FDG imaging pattern in AD group was presented as focal hypometabolism in posterior cingutate,superior frontal lobe,inferior frontal lobe, superior parietal lobe and lateral temporal lobe.PIB retention was mainly in bilateral superior frontal lobe,inferior frontal lobe,superior parietal lobe,lateral temporal lobe and posterior cingulate gyrus in images of equilibrium phase.The two FDG imaging results were basically in agreement with each other.Conclusion PIB with combined FDG PET imaging can provide more accurate information in diagnosis of AD.Further study is needed to confirm the effectiveness and practicability of this technology.
RESUMO
Objective To investigate the diagnostic value of dual-tracer PET imaging in Alzheimer's disease (AD).Methods For this study,we enrolled 11 patients who were diagnosed clinically with AD and 7 age-matched healthy controls who underwent 11 C-PIB and 18 F-FDG PET brain imaging in the same period.Visual evaluation was used to observe the distribution of tracers.ROI technology and brain metabolism analysis software were used to quantify the uptake levels of PIB and FDG.Results Compared with that in HC group,FDG imaging pattern in AD group was presented as focal hypometabolism in posterior cingutate,superior frontal lobe,inferior frontal lobe, superior parietal lobe and lateral temporal lobe.PIB retention was mainly in bilateral superior frontal lobe,inferior frontal lobe,superior parietal lobe,lateral temporal lobe and posterior cingulate gyrus in images of equilibrium phase.The two FDG imaging results were basically in agreement with each other.Conclusion PIB with combined FDG PET imaging can provide more accurate information in diagnosis of AD.Further study is needed to confirm the effectiveness and practicability of this technology.
RESUMO
Objective To discuss the value of dual-time-point 18FDG PET-CT imaging on involved field radiotherapy for hilar and mediastinal metastatic lymph nodes in patients with non-small cell lung cancer (NSCLC).Methods Fifty-four patients with NSCLC were included in this analysis,including 34 men and 20 women with mean age of 59(34-76)years.Two sequential PET-CT scans given 3-5 days before surgery were standard single-time-point imaging for the whole body and delayed imaging for the thorax.The pathologic data were used as golden standard to determine the difference between the standard single-time-point and dual-time-point FET-CT imaging in the definition of gross target volume(GTV)of involved-field radiotherapy for metastatic lymph nodes. Results For hilar metastatic lymph nodes,the GTV defined by single-time-point imaging was consistent with pathologic GTV in 21 patients(39%),comparing with 31 patients(57%) by dual-time-point imaging.Using pathologic data as golden standard,GTV alteration defined by single-time-point imaging had statisticaly significant difference comparing with that defined by dual-time-point imaging(u=519.00,P=0.023).For mediastinal metastatic lymph nodes,the GTV defined by single-time-point imaging was consistent with pathologic GTV in 30 patients(56%),comparing with 36 patients(67%)by dual-time-point imaging.Using pathologic data as golden standard.GTV alteration defined by single-time-point imaging had no statisticaly significant difference comparing with that defined by dual-time-point imaging(u=397.50,P=0.616).Conclusions For patients with NSCLC receiving involved-field radiotherapy,GTV definition for hilar and mediastinal metastatic lymph nodes by dual-time-point imaging is more consistent with that by pathologic data.Dual-time-point imaging has a larger value in terms of target delineation for hilar and mediastinal metastatic lymph nodes.
RESUMO
Purpose:To evaluate ~(18)F-deoxyglucose dual-head tomography with hPET in the detection of suspected recurrence in non-small cell lung cancer, as compared with CT/MRI imaging. Methods:21 patients with clinically suspected recurrences in non-small-cell lung cancer underwent ~(18)F-FDG hPET and CT/MRI imaging. The final diagnosis of recurrence was proved by pathology or clinical following-up. Results:The ~(18)F-FDG hPET sensitivity, specificity,accuracy,postive predictive value in defining local recurrence were 94.1%,75%,90.5 %,94.1%,respectively ; and those of CT/MRI were 60%,66.7%,61.9%,81.8%, respectively. Conclusions:In comparison with CT/MRI,~(18)F-FDG hPET possesses a higher sensitivity、specificity and accuracy in detecting recurrence in non-small-cell lung cancer.~(18)FDG hPET is quite valuable methd to define the tanget in the radiotherapy of recunent non-small-cell lung cancer,and is less expensive than PET.It is thus recommended for clinical use.